Ipsen posts 5% sales growth for 3rd-qtr 2012
French drugmaker Ipsen (Euronext: IPN) yesterday reported third-quarter 2012 financial results with 5% growth in group sales to 294.9 million euros ($381.4 million), with total drug turnover up 4.9% to 286.8 million euros, driven by 14.9% growth in specialty care sales to 212.4 million euros, offset by 16% decline in primary care sales to 74.4 million euros.
For full year 2012, the company expects Specialty care drug sales to grow around 10%; primary care drug sales to decrease about 15%; and recurring adjusted operating margin of about 15% of sales.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze